Jun 26, 2009 by Brian Orelli, PhDChange at Top Looks Good for Bottom LineInvestors welcome Boston Scientific's new boss.
Jun 26, 2009 by Brian Orelli, PhDNovartis Leads the PackBiosimilars come to Japan; will the U.S. be next?
Jun 26, 2009 by Brian Orelli, PhDLooking for a Sliver of the Me-Too PieAnother diabetes drug is close to hitting the market.
Jun 26, 2009 by Brian Orelli, PhDRumors and Safety Issues -- One Bad Combinationsanofi-aventis takes one on the chin.
Jun 25, 2009 by Brian Orelli, PhDPfizer Gets a DoubleSutent looks good, but how many sales can it bring?
Jun 24, 2009 by Brian Orelli, PhDBoston Scientific Helps Itself ... and Its RivalsWith rivals like these, who needs friends?
Jun 19, 2009 by Brian Orelli, PhDComparative Medicine Could Sink Your StocksDoes comparative medicine mean the death of the me-too drug? Or your stocks?
Jun 19, 2009 by Brian Orelli, PhDA Meaningless FDA Approval ... for NowNovartis' drug is approved to treat a few hundred people.
Jun 17, 2009 by Brian Orelli, PhDSavient Saves and Moves UpThe FDA advisory panel gives Savient's Krystexxa a passing grade.
Jun 16, 2009 by Brian Orelli, PhDGoing Viral, but Not in a Good WayGenzyme's infected with manufacturing issues.
Jun 15, 2009 by Brian Orelli, PhDStrange BedfellowsA pharmaceutical- and generic-drug company teaming up?
Jun 12, 2009 by Brian Orelli, PhDBe Careful What You Wish For Do you have the stomach to profit from swine flu?
